Search results for "immunomodulation"

showing 10 items of 118 documents

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-modulation: Comparison and Potential Opportunities

2017

In recent years, high-intensity focused ultrasound (HIFU) has emerged as a new and promising non-invasive and non-ionizing ablative technique for the treatment of localized solid tumors. Extensive pre-clinical and clinical studies have evidenced that, in addition to direct destruction of the primary tumor, HIFU-thermoablation may elicit long-term systemic host anti-tumor immunity. In particular, an important consequence of HIFU treatment includes the release of tumor-associated antigens (TAAs), the secretion of immuno-suppressing factors by cancer cells and the induction of cytotoxic T lymphocyte (CTL) activity. Radiation therapy (RT) is the main treatment modality used for many types of tu…

0301 basic medicinePathologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingAcoustics and Ultrasonicsmedicine.medical_treatmentBiophysicsImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsmedicineBystander effectHumansCancerChemotherapyRadiological and Ultrasound Technologybusiness.industryCancermedicine.diseasePrimary tumorThermal ablationHigh-intensity focused ultrasoundRadiation therapyImmuno-therapyRadiation therapyTumor vaccine030104 developmental biologyBiophysicHigh-intensity focused ultrasound030220 oncology & carcinogenesisCancer cellCancer researchHigh-Intensity Focused Ultrasound AblationAnti-tumor immunitybusinessAnti-tumor immunity; Cancer; High-intensity focused ultrasound; Immuno-therapy; Radiation therapy; Thermal ablation; Tumor vaccine
researchProduct

Life history adjustments to intestinal inflammation in a gut nematode.

2017

ABSTRACT Many parasitic nematodes establish chronic infections. This implies a finely tuned interaction with the host immune response in order to avoid infection clearance. Although a number of immune interference mechanisms have been described in nematodes, how parasites adapt to the immune environment provided by their hosts remains largely unexplored. Here, we used the gastrointestinal nematode Heligmosomoides polygyrus to investigate the plasticity of life history traits and immunomodulatory mechanisms in response to intestinal inflammation. We adopted an experimental model of induced colitis and exposed worms to intestinal inflammation at two different developmental stages (larvae and …

0301 basic medicinePhysiologyPhenotypic plasticityAquatic ScienceHost-Parasite InteractionsImmunomodulation03 medical and health sciencesMice0302 clinical medicineImmune systemparasitic diseases[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/Symbiosismedicine[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyAnimalsColitisAdaptationIntestinal Diseases ParasiticMolecular BiologyLife History TraitsEcology Evolution Behavior and SystematicsStrongylida InfectionsInfectivityInflammationStrongyloideaPhenotypic plasticityMice Inbred BALB CbiologyHost (biology)Dextran SulfateInflammatory responseHelminth Proteinsmedicine.diseasebiology.organism_classification3. Good healthIntestinesDisease Models Animal030104 developmental biologyNematodeInfectivityInsect ScienceLarvaImmunology[SDV.IMM]Life Sciences [q-bio]/ImmunologyAnimal Science and ZoologyHeligmosomoides polygyrusAdaptation030215 immunology[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/SymbiosisThe Journal of experimental biology
researchProduct

The Immunomodulatory Properties of the Human Amnion-Derived Mesenchymal Stromal/Stem Cells Are Induced by INF-γ Produced by Activated Lymphomonocytes…

2020

Human mesenchymal stromal/stem cells (MSCs), being immunoprivileged and having immunomodulatory ability, represent a promising tool to be applied in the field of regenerative medicine. Based on numerous in vitro evidences, the immunological effects of MSCs on immune cells could depend on different mechanisms as cell-to-cell contact and paracrine signals. Furthermore, recent studies have shown that the immunomodulatory activity of MSCs is initiated by activated immune cells; thus, their interaction represents a potential homeostatic mechanism by which MSCs regulate the immune response. MSCs also release exosomes able to give different effects, in a paracrine manner, by influencing inflammato…

0301 basic medicineProgrammed Cell Death 1 ReceptorCell CommunicationLymphocyte ActivationimmunomodulationB7-H1 AntigenMonocytes0302 clinical medicineImmunology and AllergyOriginal ResearchChemistryCell DifferentiationHealthy VolunteersI-kappa B KinaseCell biologymedicine.anatomical_structureprimed-hAMSCsMonocyte differentiationCytokinesStem celllcsh:Immunologic diseases. AllergyStromal cellT cellPrimary Cell CultureImmunologyregenerative medicineexosomesInterferon-gamma03 medical and health sciencesParacrine signallingImmune systeminterferon-γmedicineHumansImmunologic FactorsAmnionhuman amnion-derived mesenchymal stem cellsCell ProliferationImmunosuppression TherapyPDL-1Mesenchymal stem cellImmunityM2-like monocytesMesenchymal Stem CellsCoculture TechniquesMicrovesiclesMicroRNAs030104 developmental biologyLeukocytes Mononuclearlcsh:RC581-607Interferon Regulatory Factor-1030215 immunologyFrontiers in Immunology
researchProduct

An RNA toolbox for cancer immunotherapy.

2018

Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to r…

0301 basic medicineSequence analysismedicine.medical_treatmentComputational biologyBiologyCancer VaccinesCell therapyImmunomodulation03 medical and health sciencesImmune systemCancer immunotherapyNeoplasmsDrug DiscoveryGene expressionmedicineAnimalsHumansPharmacologyRegulation of gene expressionRNACancerGeneral Medicinemedicine.disease030104 developmental biologyRNARNA InterferenceImmunotherapyNature reviews. Drug discovery
researchProduct

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

2019

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of i…

0301 basic medicineSettore BIO/17 - IstologiaB7 AntigensT cellIn Vitro TechniquesBiologyLymphocyte ActivationRegenerative medicineCell therapyUmbilical CordImmune toleranceImmunomodulation03 medical and health sciences0302 clinical medicineWharton's jellymedicineHumansWharton JellyCD276Cells CulturedCell ProliferationStem cellMesenchymal stem cellCell DifferentiationMesenchymal Stem CellsHuman umbilical cordCell biologyTransplantationTolerance induction030104 developmental biologymedicine.anatomical_structureB7-H3030220 oncology & carcinogenesisLymphocyte inhibitionRegenerative medicineCytokinesWharton’s jelly mesenchymal stromal cellsStem cell
researchProduct

Comparative study of the production of soluble factors in human placenta-derived mesenchymal stromal/stem cells grown in adherent conditions or as ag…

2019

Abstract Different approaches have been studied in both preclinical and clinical settings to develop cell-based therapies and/or engineered cell-based therapies to better integrate grafts with the host. In these techniques, much attention is addressed to the use of adult stem cells such as mesenchymal stem cells (MSCs), but identifying and obtaining sufficient numbers of therapeutic cells, and the right route of administration, is often a challenge. In this study, we tested the feasibility of encapsulating human amnion-derived MSCs (hAMSCs) in a semipermeable and biocompatible fiber as a new approach for regenerative medicine. Our data showed that hAMSCs aggregated in the device constitutes…

0301 basic medicineStromal cellAngiogenesisCell SurvivalPlacentaCellBiophysicsCell Culture TechniquesBiocompatible MaterialsBiologyParacrine effectsBiochemistryRegenerative medicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemCell MovementPregnancymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansImmunologic FactorsAmnionMolecular BiologyCell AggregationSettore MED/04 - Patologia GeneraleCatheter-like devicePlacenta-derived stromal/stem cellsSettore BIO/16 - Anatomia UmanaMesenchymal stem cellMesenchymal Stem CellsCell BiologyCells Immobilized030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisRegenerative medicineCancer researchAngiogenesis Inducing AgentsFemaleAngiogenesisStem cellAdult stem cell
researchProduct

Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells

2017

Designing of CD8 T cell vaccines which would provide protection against tumors is still considered a great challenge in immunotherapy. Here we show a robust potential of a cytomegalovirus (CMV) vector expressing the NKG2D ligand RAE-1γ as CD8 T cell-based vaccine against malignant tumors. Immunization with the CMV vector expressing RAE-1γ delayed tumor growth or even provided complete protection against tumor challenge in both prophylactic and therapeutic settings. Moreover, a potent tumor control in mice vaccinated with this vector can be further enhanced by blocking the immune checkpoints TIGIT and PD-1. Expression of RAE-1γ by the CMV vector potentiated expansion of KLRG1+ CD8 T cells wi…

0301 basic medicineTumor vaccine [RAE-1γ]medicine.medical_treatmentT cellImmunologyGenetic VectorsProgrammed Cell Death 1 ReceptorMelanoma ExperimentalCytomegalovirusEpitopes T-LymphocyteBiologyCD8-Positive T-LymphocytesCancer VaccinesArticleCMV vectorNKG2DImmunomodulation03 medical and health sciencesMiceImmune systemTIGITKLRG1+ CD8+ T cellsNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansRAE-1γ : Tumor vaccineLectins C-TypeReceptors ImmunologicαTIGIT ; CMV vector ; KLRG1+ CD8+ T cells ; NKG2D ; RAE-1γ : Tumor vaccineBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Membrane ProteinsImmunotherapyNKG2DVirology3. Good healthKiller Cells NaturalDisease Models Animal030104 developmental biologymedicine.anatomical_structureImmunizationAnimals NewbornFemaleαTIGITImmunotherapyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8
researchProduct

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

2020

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs …

0301 basic medicinefunction recoverymedicine.medical_specialtyPopulationimmunomodulationGastroenterologyPathology and Forensic MedicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicinecell transplantationAdverse effecteducationSettore MED/04 - Patologia Generalemesenchymal stem cellseducation.field_of_studybusiness.industryMesenchymal stem cellCOVID-19Cell Biologymedicine.diseaseFunction recoveryACE2 negativeTransplantationPneumonia030104 developmental biologyMesenchymal stem cellsNeurology (clinical)Cell transplantationGeriatrics and GerontologybusinessCytokine storm030217 neurology & neurosurgeryCD8Aging and disease
researchProduct

Modulation of the Immune System for the Treatment of Glaucoma

2017

Background At present intraocular pressure (IOP) lowering therapies are the only approach to treat glaucoma. Neuroprotective strategies to protect the retinal ganglion cells (RGC) from apoptosis are lacking to date. Substantial amount of research concerning the role of the immune system in glaucoma has been performed in the recent years. This review aims to analyse changes found in the peripheral immune system, as well as selected local changes of retina immune cells in the glaucomatous retina. Methods By dividing the immune system into the innate and the adaptive immune system, a systematic literature research was performed to find recent approaches concerning the modulation of the immune …

0301 basic medicinegenetic structuresT cellsGlaucomaAdaptive ImmunityRetinal ganglionArticleImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemAntigenmedicineAnimalsHumansPharmacology (medical)PharmacologyB cellsToll-like receptorRetinabiologybusiness.industryGeneral Medicinemedicine.diseaseAcquired immune systemImmunity Innateeye diseasesimmune systemPsychiatry and Mental healthglaucoma030104 developmental biologymedicine.anatomical_structureNeurologyImmunologybiology.proteinneuroprotectionsense organsNeurology (clinical)Antibodybusiness030217 neurology & neurosurgeryCurrent Neuropharmacology
researchProduct